Two new requests for proposals released by BARDA and NIAID

Two new requests for proposals released by BARDA and NIAID

  • 25/01/2022

Just recently, NIAID and BARDA both have published requests for proposals for the areas of therapeutics (antibacterial, antifungal, antiviral), vaccines (again, all 3 areas), and diagnostics. The release covers both biothreat pathogens and the NIAID list of Emerging Diseases/Pathogens.

More concretely, BARDA calls for proposals to use Project Bioshield funds to support the late-stage development, regulatory approval, and potential procurement of an antibiotic for the treatment of infections due to biothreat pathogens. Here, antibacterials agaist the following pathogens are within scope: Yersinia pestis, Francisella tularensis, Burkholderia pseudomallei. Conversely, Bacillus anthracis will not be included.

NIAID has published a Broad Agency Announcement (HHS-NIH-NIAID-BAA2022-1) including in total four research areas, of which the first is (Research Area 001): “Development of Vaccine Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections, and Emerging Infectious Diseases”. Included are RNA viruses with pandemic potential (e.g., Coronaviridae) as well as Burkholderia spp, Group A & B Streptococci, Hepatitis C, Mycobacterium tuberculosis, new or improved vaccines against Streptococcus pneumoniae, Bordetella pertussis, and Tick-borne viruses. Furthermore, also included arevaccines for resistant gram-negatives, such as, but not only, Pseudomonas aeruginosa, Escherichia coli, Salmonella, and Shigella spp; as well as vaccinesfor MDR gram-positives, e.g. Staphylococcus aureus and Mycobacterium tuberculosis. Lastly, the request for proposals also includes vaccines targeted at fungal pathogens (e.g. Candida auris, Aspergillus fumigatus).

The NIAID call is complemented by the two other areas, Research Area 002: “Development of Therapeutic Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections, and Emerging Infectious Diseases” and Research Area 003: “The Antiviral Program for Pandemics (APP): Development of Antivirals for Specific RNA Viral Families of Pandemic Potential” and lastly Research Area 004: “Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections (AMR), and Emerging Infectious Diseases”. All important details for both the BARDA and NIAID requests for proposals can be found in the linked pages below.

Learn more about the BARDA call here: https://sam.gov/opp/dc1a1411637d44e28898e36a99fd6fcf/view

Read the details about the call by NIAID: https://sam.gov/opp/7be6deac410e4e4789555c72254d3f4d/view